PHOENIX BIOTECH ACQUISITION CORP.

CERo Therapeutics Advances Novel CER-T Cell Therapy for AML with Invivoscribe Diagnostic Support

- CERo Therapeutics has initiated a Phase 1 clinical trial for CER-1236, a novel Chimeric Engulfment Receptor T-cell (CER-T) therapy targeting acute myeloid leukemia patients who are relapsed/refractory, in remission with MRD, or newly diagnosed with TP53-mutated MDS/AML. - The company's proprietary CER-T platform integrates innate and adaptive immunity characteristics to employ phagocytic mechanisms for tumor destruction, potentially offering broader therapeutic applications than current CAR-T therapies across both hematological malignancies and solid tumors. - Invivoscribe's LabPMM laboratories provide critical diagnostic support through customized multiparametric flow cytometry services and validated AML MRD assays to ensure product purity and assess therapeutic response. - CER-1236 recently received FDA Orphan Drug Designation for AML treatment, highlighting the clinical potential of this next-generation engineered T-cell therapeutic approach.